Apexigen Presents New Data from a Phase 2 Trial Evaluating

-Sotigalimab in combination with neoadjuvant chemoradiation induced higher pathologic complete response rates, an important predictor of survival, in...

Related Keywords

Paris ,France General ,France ,Andrew Ko ,Frank Hsu ,Bruce Mackle ,William Duke ,Apexigen Inc ,Securities Exchange ,University Of California San Francisco ,European Society For Medical Oncology ,Nasdaq ,European Society ,Medical Oncology ,Clinical Medicine ,California San Francisco ,Principal Investigator ,Chief Medical Officer ,Guillain Barre Syndrome ,California San ,Session Date ,Securities Act ,Securities Exchange Act ,Nasdaq Apgn ,Apexigen ,